<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39384158</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0984</ISSN><JournalIssue CitedMedium="Internet"><Volume>331</Volume><PubDate><Year>2024</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>Journal of virological methods</Title><ISOAbbreviation>J Virol Methods</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the Seegene Allplex™ RV master assay for one-step simultaneous detection of eight respiratory viruses in nasopharyngeal specimens.</ArticleTitle><Pagination><StartPage>115042</StartPage><MedlinePgn>115042</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jviromet.2024.115042</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0166-0934(24)00166-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Seegene Allplex™ RV Master (RVM) assay is a one-step multiplex real-time reverse transcription polymerase chain reaction (RT-PCR) system for detecting eight viral respiratory pathogens from nasopharyngeal swab, aspirate, and bronchoalveolar lavage specimens. The eight RVM targets are: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), Influenza B (Flu B), Human respiratory syncytial virus (RSV), adenovirus (AdV), rhinovirus (HRV), parainfluenza virus (PIV), and metapneumovirus (MPV). The assay is based on Seegene's multiple detection temperature (MuDT) technology and provides cycle threshold (Ct) values for each of its viral targets upon PCR completion.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We aimed to evaluate the diagnostic performance of the RVM assay by calculating sensitivity, specificity, accuracy, Positive Predictive Value (PPV), Negative Predictive Value (NPV), Positive Percent Agreement (PPA), Negative Percent Agreement (NPA), and Overall Percent Agreement (OPA) compared to definite diagnosis and analogous reference assays.</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Diagnostic sensitivity, specificity, accuracy, PPV, and NPV were calculated by comparing the results of the RVM assay to that of definite diagnosis assays; while PPA, NPA, and OPA were calculated by comparing results of the RVM assay to that of analogous reference products. Definite diagnosis and reference methods comprised whole genome sequencing and PCR genotyping, the Allplex™ SARS-CoV-2/FluA/FluB/RSV and Respiratory Panels 1, 2, and 3 assays (Seegene), and the Xpert® Xpress SARS-CoV-2/FluA/FluB/RSV Plus assay (Cepheid). Reproducibility of the RVM assay using fully-automated and semi-automated nucleic acid (NA) extraction workflows and as performed by independent operators was also assessed. In total, 249 positive respiratory specimens and at least 50 negative specimens for each target tested were used for this evaluation study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sensitivity, specificity, accuracy, PPV, NPV, PPA, NPA, and OPA ranged from 95.7 % to 100 % for detecting all eight targets tested on the RVM assay. Reproducibility PPA, NPA, and OPA between automated and semi-automated NA extraction workflows were all &gt;97.9 %, while the reproducibility PPA, NPA and OPA between independent operators were all 100 %.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results demonstrate a high level of sensitivity, specificity, accuracy and diagnostic predictive value of the RVM assay and high agreement with comparable reference assays in identifying all eight of its targets. Taken together, our study underscores the diagnostic utility of the RVM assay in detecting eight viral respiratory pathogens.</AbstractText><CopyrightInformation>Copyright © 2024. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mdunyelwa</LastName><ForeName>Anele</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ndlovu Research Centre, Ndlovu Laboratories, Elandsdoorn, Dennilton, Limpopo, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seema</LastName><ForeName>Colette</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ndlovu Research Centre, Ndlovu Laboratories, Elandsdoorn, Dennilton, Limpopo, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mabaso</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ndlovu Research Centre, Ndlovu Laboratories, Elandsdoorn, Dennilton, Limpopo, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mlambo</LastName><ForeName>Khamusi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Ndlovu Research Centre, Ndlovu Laboratories, Elandsdoorn, Dennilton, Limpopo, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mtsweni</LastName><ForeName>Mandisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ndlovu Research Centre, Ndlovu Laboratories, Elandsdoorn, Dennilton, Limpopo, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maphanga</LastName><ForeName>Mathapelo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ndlovu Research Centre, Ndlovu Laboratories, Elandsdoorn, Dennilton, Limpopo, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rammutla</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Ndlovu Research Centre, Ndlovu Laboratories, Elandsdoorn, Dennilton, Limpopo, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tempelman</LastName><ForeName>Hugo A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Ndlovu Research Centre, Ndlovu Laboratories, Elandsdoorn, Dennilton, Limpopo, South Africa; Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa; Utrecht University, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umunnakwe</LastName><ForeName>Chijioke N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Ndlovu Research Centre, Ndlovu Laboratories, Elandsdoorn, Dennilton, Limpopo, South Africa. Electronic address: cumunnakwe@ndlovu.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Virol Methods</MedlineTA><NlmUniqueID>8005839</NlmUniqueID><ISSNLinking>0166-0934</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Influenza viruses</Keyword><Keyword MajorTopicYN="N">Laboratory Testing</Keyword><Keyword MajorTopicYN="N">Molecular Diagnostics</Keyword><Keyword MajorTopicYN="N">Multiplex RT-PCR</Keyword><Keyword MajorTopicYN="N">Performance evaluation</Keyword><Keyword MajorTopicYN="N">Real-time PCR</Keyword><Keyword MajorTopicYN="N">Respiratory infections</Keyword><Keyword MajorTopicYN="N">Respiratory viruses</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Seegene Allplex RV Master</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None of the authors of this manuscript have any conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>19</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39384158</ArticleId><ArticleId IdType="doi">10.1016/j.jviromet.2024.115042</ArticleId><ArticleId IdType="pii">S0166-0934(24)00166-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle>